Market Access News | pharmaphorum

News

After years of delays, NICE backs Celgene's Revlimid in firs...

After years of delays caused by wrangling over price, NICE has recommended regular NHS funding for Celgene’s Revlimid in combination with dexamethasone, as an option for certain adults with

News

Gilead faces lawsuit over HIV drug pricing

Gilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving HIV drugs from entering the market.

News

NHS chief hails SMA drug deal - and was that a swipe at Vert...

Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s super-expensive new drug Spinraza after the manufacturer struck a deal wit

News

Teva vows to fight price-fixing lawsuit

Teva has said it will defend itself against a lawsuit raised by 44 US states that alleges the company was the ringleader in an illegal price-fixing scheme involving 19 other generic compani

News

Gilead to donate HIV drug to US government prophylaxis schem...

Gilead has announced it will donate its HIV drug Truvada to a US-government led prophylaxis programme to end the epidemic of the disease.

News

NICE backs Ocrevus for PPMS in England - but with caveats

Patients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for the condition after NICE recommended regular NHS funding for Roche's Ocrevu

After years of delays, NICE backs Celgene's Revlimid in firs...

Gilead faces lawsuit over HIV drug pricing

NHS chief hails SMA drug deal - and was that a swipe at Vert...

Teva vows to fight price-fixing lawsuit

Gilead to donate HIV drug to US government prophylaxis schem...

NICE backs Ocrevus for PPMS in England - but with caveats

Tarsus places $800m wager on Alkeus' Stargardt therapy

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks